Breaking News, Financial News

Financial Report: Roche 3Q

Pharmaceutical sales were up 2% attributed to Avastin, MabThera/Rituxan, Herceptin, Lucentis, Actemra/RoActemra and Xeloda.

Roche 3Q

3Q Revenues: $12.1 billion (+2%)

YTD Revenues:
$37.0 billion (+3%)

Comments:
Pharmaceutical sales were up 2% attributed to Avastin, MabThera/Rituxan, Herceptin, Lucentis, Actemra/RoActemra and Xeloda. Sales of cancer medicines were up 8% in the quarter. Revenues in the quarter were negatively impacted by lower demand for Tamiflu. Roche’s Diagnostics Division revenue was up 9% driven mainly by professional diagnostics and diabetes care.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters